French contrast developer Guerbet will start selling two new microcatheters in the third quarter of 2018 for use in tumor and vascular aneurysm embolization procedures.
The SeQure and DraKon microcatheters are designed to enhance intra-arterial navigation and enable interventional radiologists to perform embolization procedures to access arteries and vascular tumors in complex cases such as renal and lung tumor embolization, prostatic artery embolization, hemorrhages, and vascular anomalies, according to Guerbet.
SeQure can help reduce the risk of nontargeted embolization with its fluid barrier technology and improve the delivery of drugs and embolic agents into tumors, whereas DraKon is most suitable for simple embolization cases, the company noted. Both received clearance from the U.S. Food and Drug Administration (FDA) on January 26, 2018.
Guerbet obtained the two microcatheters after its acquisition of Israel-based microcatheter developer Accurate Medical Therapeutics. It is currently presenting SeQure and DraKon at the Global Embolization Symposium and Technologies (GEST) 2018 in Miami.
